Reirradiation for recurrent craniopharyngioma
Reirradiation is rarely administered to patients with recurrent craniopharyngioma owing to concerns regarding visual and endocrine side effects. The purpose of this case series was to evaluate our institutional experience of patients with craniopharyngioma treated with 2 courses of fractionated radi...
Gespeichert in:
Veröffentlicht in: | Advances in radiation oncology 2020-11, Vol.5 (6), p.1305-1310 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1310 |
---|---|
container_issue | 6 |
container_start_page | 1305 |
container_title | Advances in radiation oncology |
container_volume | 5 |
creator | Foran, Sarah J. Laperriere, Normand Edelstein, Kim Janzen, Laura Tadic, Tony Ramaswamy, Vijay Shultz, David Gentili, Fred Bouffet, Eric Tsang, Derek S. |
description | Reirradiation is rarely administered to patients with recurrent craniopharyngioma owing to concerns regarding visual and endocrine side effects. The purpose of this case series was to evaluate our institutional experience of patients with craniopharyngioma treated with 2 courses of fractionated radiation therapy.
A retrospective study was performed of all patients with craniopharyngioma treated with 2 courses of fractionated radiation therapy at a single institution. Electronic medical records and radiation therapy records were reviewed.
We identified 4 eligible patients with recurrent craniopharyngioma. With a median follow-up of 33 months after reirradiation, 3 patients attained disease control; 1 patient developed progressive disease, 27 months after reirradiation. In 3 evaluable patients, vision remained stable or improved after reirradiation; one patient had no light perception before reirradiation. None of the patients experienced additional endocrine toxicities after reirradiation, apart from one patient who had low serum thyroid stimulating hormone before reirradiation and later developed hypothyroidism after treatment.
Reirradiation may represent a safe and effective therapeutic option for selected patients with recurrent, refractory craniopharyngioma and without other salvage treatment options. Larger studies with longer-term follow up are warranted to better understand outcomes in these patients. |
doi_str_mv | 10.1016/j.adro.2020.07.020 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7718531</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2452109420302116</els_id><sourcerecordid>2483406625</sourcerecordid><originalsourceid>FETCH-LOGICAL-c455t-667bc77e920a0d468287fa367eca22652420a5df7b31f3ae2748f76f85e9a4fc3</originalsourceid><addsrcrecordid>eNp9kE1LAzEYhIMottT-AQ_So5dd850tiCDFLygIoueQZt-0Ke2mJrsF_70prVIvnibwzkyGB6FLgkuCibxZlqaOoaSY4hKrMssJ6lMuaEHwmJ8evXtomNIS45xiijB8jnqMMSzwmPZR8QY-RlN70_rQjFyIowi2ixGadmSjaXzYLEz8auY-rM0FOnNmlWB40AH6eHx4nzwX09enl8n9tLBciLaQUs2sUjCm2OCay4pWyhkmFVhDqRSU54OonZox4pgBqnjllHSVgLHhzrIButv3brrZGmqbx0Sz0pvo13mLDsbrv5fGL_Q8bLVSpBKM5ILrQ0EMnx2kVq99srBamQZClzTlFeNYSiqyle6tNoaUIrjfbwjWO9R6qXeo9Q61xkpnyaGr44G_kR-w2XC7N0DGtPUQdbIeGgu1z3xbXQf_X_83siKQCA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2483406625</pqid></control><display><type>article</type><title>Reirradiation for recurrent craniopharyngioma</title><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Foran, Sarah J. ; Laperriere, Normand ; Edelstein, Kim ; Janzen, Laura ; Tadic, Tony ; Ramaswamy, Vijay ; Shultz, David ; Gentili, Fred ; Bouffet, Eric ; Tsang, Derek S.</creator><creatorcontrib>Foran, Sarah J. ; Laperriere, Normand ; Edelstein, Kim ; Janzen, Laura ; Tadic, Tony ; Ramaswamy, Vijay ; Shultz, David ; Gentili, Fred ; Bouffet, Eric ; Tsang, Derek S.</creatorcontrib><description>Reirradiation is rarely administered to patients with recurrent craniopharyngioma owing to concerns regarding visual and endocrine side effects. The purpose of this case series was to evaluate our institutional experience of patients with craniopharyngioma treated with 2 courses of fractionated radiation therapy.
A retrospective study was performed of all patients with craniopharyngioma treated with 2 courses of fractionated radiation therapy at a single institution. Electronic medical records and radiation therapy records were reviewed.
We identified 4 eligible patients with recurrent craniopharyngioma. With a median follow-up of 33 months after reirradiation, 3 patients attained disease control; 1 patient developed progressive disease, 27 months after reirradiation. In 3 evaluable patients, vision remained stable or improved after reirradiation; one patient had no light perception before reirradiation. None of the patients experienced additional endocrine toxicities after reirradiation, apart from one patient who had low serum thyroid stimulating hormone before reirradiation and later developed hypothyroidism after treatment.
Reirradiation may represent a safe and effective therapeutic option for selected patients with recurrent, refractory craniopharyngioma and without other salvage treatment options. Larger studies with longer-term follow up are warranted to better understand outcomes in these patients.</description><identifier>ISSN: 2452-1094</identifier><identifier>EISSN: 2452-1094</identifier><identifier>DOI: 10.1016/j.adro.2020.07.020</identifier><identifier>PMID: 33305092</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Scientific</subject><ispartof>Advances in radiation oncology, 2020-11, Vol.5 (6), p.1305-1310</ispartof><rights>2020 The Authors</rights><rights>2020 The Authors.</rights><rights>2020 The Authors 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c455t-667bc77e920a0d468287fa367eca22652420a5df7b31f3ae2748f76f85e9a4fc3</citedby><cites>FETCH-LOGICAL-c455t-667bc77e920a0d468287fa367eca22652420a5df7b31f3ae2748f76f85e9a4fc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718531/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718531/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33305092$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Foran, Sarah J.</creatorcontrib><creatorcontrib>Laperriere, Normand</creatorcontrib><creatorcontrib>Edelstein, Kim</creatorcontrib><creatorcontrib>Janzen, Laura</creatorcontrib><creatorcontrib>Tadic, Tony</creatorcontrib><creatorcontrib>Ramaswamy, Vijay</creatorcontrib><creatorcontrib>Shultz, David</creatorcontrib><creatorcontrib>Gentili, Fred</creatorcontrib><creatorcontrib>Bouffet, Eric</creatorcontrib><creatorcontrib>Tsang, Derek S.</creatorcontrib><title>Reirradiation for recurrent craniopharyngioma</title><title>Advances in radiation oncology</title><addtitle>Adv Radiat Oncol</addtitle><description>Reirradiation is rarely administered to patients with recurrent craniopharyngioma owing to concerns regarding visual and endocrine side effects. The purpose of this case series was to evaluate our institutional experience of patients with craniopharyngioma treated with 2 courses of fractionated radiation therapy.
A retrospective study was performed of all patients with craniopharyngioma treated with 2 courses of fractionated radiation therapy at a single institution. Electronic medical records and radiation therapy records were reviewed.
We identified 4 eligible patients with recurrent craniopharyngioma. With a median follow-up of 33 months after reirradiation, 3 patients attained disease control; 1 patient developed progressive disease, 27 months after reirradiation. In 3 evaluable patients, vision remained stable or improved after reirradiation; one patient had no light perception before reirradiation. None of the patients experienced additional endocrine toxicities after reirradiation, apart from one patient who had low serum thyroid stimulating hormone before reirradiation and later developed hypothyroidism after treatment.
Reirradiation may represent a safe and effective therapeutic option for selected patients with recurrent, refractory craniopharyngioma and without other salvage treatment options. Larger studies with longer-term follow up are warranted to better understand outcomes in these patients.</description><subject>Scientific</subject><issn>2452-1094</issn><issn>2452-1094</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kE1LAzEYhIMottT-AQ_So5dd850tiCDFLygIoueQZt-0Ke2mJrsF_70prVIvnibwzkyGB6FLgkuCibxZlqaOoaSY4hKrMssJ6lMuaEHwmJ8evXtomNIS45xiijB8jnqMMSzwmPZR8QY-RlN70_rQjFyIowi2ixGadmSjaXzYLEz8auY-rM0FOnNmlWB40AH6eHx4nzwX09enl8n9tLBciLaQUs2sUjCm2OCay4pWyhkmFVhDqRSU54OonZox4pgBqnjllHSVgLHhzrIButv3brrZGmqbx0Sz0pvo13mLDsbrv5fGL_Q8bLVSpBKM5ILrQ0EMnx2kVq99srBamQZClzTlFeNYSiqyle6tNoaUIrjfbwjWO9R6qXeo9Q61xkpnyaGr44G_kR-w2XC7N0DGtPUQdbIeGgu1z3xbXQf_X_83siKQCA</recordid><startdate>20201101</startdate><enddate>20201101</enddate><creator>Foran, Sarah J.</creator><creator>Laperriere, Normand</creator><creator>Edelstein, Kim</creator><creator>Janzen, Laura</creator><creator>Tadic, Tony</creator><creator>Ramaswamy, Vijay</creator><creator>Shultz, David</creator><creator>Gentili, Fred</creator><creator>Bouffet, Eric</creator><creator>Tsang, Derek S.</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20201101</creationdate><title>Reirradiation for recurrent craniopharyngioma</title><author>Foran, Sarah J. ; Laperriere, Normand ; Edelstein, Kim ; Janzen, Laura ; Tadic, Tony ; Ramaswamy, Vijay ; Shultz, David ; Gentili, Fred ; Bouffet, Eric ; Tsang, Derek S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c455t-667bc77e920a0d468287fa367eca22652420a5df7b31f3ae2748f76f85e9a4fc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Scientific</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Foran, Sarah J.</creatorcontrib><creatorcontrib>Laperriere, Normand</creatorcontrib><creatorcontrib>Edelstein, Kim</creatorcontrib><creatorcontrib>Janzen, Laura</creatorcontrib><creatorcontrib>Tadic, Tony</creatorcontrib><creatorcontrib>Ramaswamy, Vijay</creatorcontrib><creatorcontrib>Shultz, David</creatorcontrib><creatorcontrib>Gentili, Fred</creatorcontrib><creatorcontrib>Bouffet, Eric</creatorcontrib><creatorcontrib>Tsang, Derek S.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Advances in radiation oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Foran, Sarah J.</au><au>Laperriere, Normand</au><au>Edelstein, Kim</au><au>Janzen, Laura</au><au>Tadic, Tony</au><au>Ramaswamy, Vijay</au><au>Shultz, David</au><au>Gentili, Fred</au><au>Bouffet, Eric</au><au>Tsang, Derek S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reirradiation for recurrent craniopharyngioma</atitle><jtitle>Advances in radiation oncology</jtitle><addtitle>Adv Radiat Oncol</addtitle><date>2020-11-01</date><risdate>2020</risdate><volume>5</volume><issue>6</issue><spage>1305</spage><epage>1310</epage><pages>1305-1310</pages><issn>2452-1094</issn><eissn>2452-1094</eissn><abstract>Reirradiation is rarely administered to patients with recurrent craniopharyngioma owing to concerns regarding visual and endocrine side effects. The purpose of this case series was to evaluate our institutional experience of patients with craniopharyngioma treated with 2 courses of fractionated radiation therapy.
A retrospective study was performed of all patients with craniopharyngioma treated with 2 courses of fractionated radiation therapy at a single institution. Electronic medical records and radiation therapy records were reviewed.
We identified 4 eligible patients with recurrent craniopharyngioma. With a median follow-up of 33 months after reirradiation, 3 patients attained disease control; 1 patient developed progressive disease, 27 months after reirradiation. In 3 evaluable patients, vision remained stable or improved after reirradiation; one patient had no light perception before reirradiation. None of the patients experienced additional endocrine toxicities after reirradiation, apart from one patient who had low serum thyroid stimulating hormone before reirradiation and later developed hypothyroidism after treatment.
Reirradiation may represent a safe and effective therapeutic option for selected patients with recurrent, refractory craniopharyngioma and without other salvage treatment options. Larger studies with longer-term follow up are warranted to better understand outcomes in these patients.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>33305092</pmid><doi>10.1016/j.adro.2020.07.020</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2452-1094 |
ispartof | Advances in radiation oncology, 2020-11, Vol.5 (6), p.1305-1310 |
issn | 2452-1094 2452-1094 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7718531 |
source | DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
subjects | Scientific |
title | Reirradiation for recurrent craniopharyngioma |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T12%3A59%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reirradiation%20for%20recurrent%20craniopharyngioma&rft.jtitle=Advances%20in%20radiation%20oncology&rft.au=Foran,%20Sarah%20J.&rft.date=2020-11-01&rft.volume=5&rft.issue=6&rft.spage=1305&rft.epage=1310&rft.pages=1305-1310&rft.issn=2452-1094&rft.eissn=2452-1094&rft_id=info:doi/10.1016/j.adro.2020.07.020&rft_dat=%3Cproquest_pubme%3E2483406625%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2483406625&rft_id=info:pmid/33305092&rft_els_id=S2452109420302116&rfr_iscdi=true |